Maxygen Announces Positive Progress in Phase IIa Clinical Trial of Nove...( -Initial 10 mcg/kg MAXY-G34 Cohort M...),Health

-Initial 10 mcg/kg MAXY-G34 Cohort Met Key Safety Criterion of Duration of

Neutropenia-

-No Serious Adverse Events or Immunogenicity to Date-

REDWOOD CITY, Calif., Jan. 7 /PRNewswire-FirstCall/ -- Maxygen, Inc. (Nasdaq: MAXY) today announced positive progress in its Phase IIa trial of MAXY-G34 for the treatment of chemotherapy-induced neutropenia. Initial observations from the trial include the following:

-- Patients in the initial 10 mcg/kg MAXY-G34 cohort met the safety

criterion for duration of neutropenia (less than or equal to five days

of severe neutropenia). In these trial conditions, severe neutropenia

typically lasts approximately seven days without G-CSF support.

-- No serious adverse events or immunogenicity issues were noted for the

initial cohort of patients on 10 mcg/kg of MAXY-G34. Data available

from multiple patients after multiple doses revealed no binding

antibodies, and drug response in all patients has been sustained.

-- The Data Safety Monitoring Board overseeing the trial approved

escalation to the second dose level of 30 mcg/kg MAXY-G34. The first

cohort of patients at this level is enrolled and currently undergoing

treatment.

-- To date, no serious adverse events or drug-related grade 3 or 4 adverse

events have been reported in any patient receiving MAXY-G34. A total of

23 doses of MAXY-G34 have been delivered to patients in the 10 mcg/kg

and 30 mcg/kg cohorts.

Russell Howard, Maxygen's chief executive officer, and Santosh Vetticaden, Maxygen's chief medical officer will present these and other details of the MAXY-G3
'/>"/>